Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells

被引:67
作者
Rescher, U [1 ]
Danielczyk, A [1 ]
Markoff, A [1 ]
Gerke, V [1 ]
机构
[1] Inst Med Biochem, Ctr Mol Biol Inflammat, D-48149 Munster, Germany
关键词
D O I
10.4049/jimmunol.169.3.1500
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The formyl peptide receptor (FPR), a heptahelical G protein-coupled receptor on phagocytic leukocytes, can be triggered by bacterially derived oligopeptides of the prototype fMLP. Although FPR expression and activation have been associated with cells of myeloid origin and bacterial inflammation, the receptor has recently been identified in nonmyeloid cells, thus suggesting additional physiological functions and the existence of an endogenous agonist. In this study, we demonstrate the presence and functional activation of the FPR in the human lung cell line A549, which represents an extrahepatic model for the regulation of acute-phase proteins. Activation of the FPR in A549 cells cannot only be triggered by fMLP, but also by an agonistic peptide of the recently identified endogenous FPR ligand, annexin 1. In addition to inducing changes in the F-actin content, annexin 1-mediated triggering of the FPR results in an increased expression of acute-phase proteins. Hence, activation of nonmyeloid FPR by its endogenous ligand annexin 1 could participate in the regulation of acute-phase responses, e.g., during inflammation and/or wound healing.
引用
收藏
页码:1500 / 1504
页数:5
相关论文
共 28 条
  • [11] Expression of functional formyl peptide receptors by human astrocytoma cell lines
    Le, YY
    Hu, JY
    Gong, WH
    Shen, WP
    Li, BQ
    Dunlop, NM
    Halverson, DO
    Blair, DG
    Wang, JM
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2000, 111 (1-2) : 102 - 108
  • [12] N-FORMYLPEPTIDE AND COMPLEMENT C5A RECEPTORS ARE EXPRESSED IN LIVER-CELLS AND MEDIATE HEPATIC ACUTE-PHASE GENE-REGULATION
    MCCOY, R
    HAVILAND, DL
    MOLMENTI, EP
    ZIAMBARAS, T
    WETSEL, RA
    PERLMUTTER, DH
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) : 207 - 217
  • [13] Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO
  • [14] 2-U
  • [15] PERETTI M, 1996, BRIT J PHARMACOL, V117, P1145
  • [16] Involvement of the receptor for formylated peptides in the in vivo anti-migratory actions of annexin 1 and its mimetics
    Perretti, M
    Getting, SJ
    Solito, E
    Murphy, PM
    Gao, JL
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) : 1969 - 1973
  • [17] SELECTIVE-INHIBITION OF NEUTROPHIL FUNCTION BY A PEPTIDE DERIVED FROM LIPOCORTIN-1 N-TERMINUS
    PERRETTI, M
    WHELLER, SK
    CHOUDHURY, Q
    CROXTALL, JD
    FLOWER, RJ
    [J]. BIOCHEMICAL PHARMACOLOGY, 1995, 50 (07) : 1037 - 1042
  • [18] Lipocortin 1 and chemokine modulation of granulocyte and monocyte accumulation in experimental inflammation
    Perretti, M
    [J]. GENERAL PHARMACOLOGY, 1998, 31 (04): : 545 - 552
  • [19] RAPID PURIFICATION OF HIGH-ACTIVITY TAQ DNA-POLYMERASE
    PLUTHERO, FG
    [J]. NUCLEIC ACIDS RESEARCH, 1993, 21 (20) : 4850 - 4851
  • [20] The N-formyl peptide receptor: A model for the study of chemoattractant receptor structure and function
    Prossnitz, ER
    Ye, RD
    [J]. PHARMACOLOGY & THERAPEUTICS, 1997, 74 (01) : 73 - 102